Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Description

Examine the effects of deutetrabenazine on functional speech and gait impairment

Conditions

Huntington Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Examine the effects of deutetrabenazine on functional speech and gait impairment

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Condition
Huntington Disease
Intervention / Treatment

-

Contacts and Locations

Nashville

Vanderbilt University Medical Center, Nashville, Tennessee, United States, 37232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of HD with documented CAG repeat ≥ 37
  • * UHDRS total maximal chorea score of ≥ 8
  • * Able to walk at least 10 meters
  • * Medically stable outpatient, based on the investigator's judgment
  • * Willing and able to give written informed consent prior to performing any study procedures
  • * Have completed at least 10th grade
  • * Montreal Cognitive Assessment score ≥ 22 on screening
  • * Female subjects of childbearing potential agree to use an acceptable method of contraception from screening through study completion
  • * Severe depression or suicidal ideation
  • * History of suicidal behavior
  • * Unstable or serious medical or psychiatric illness
  • * Renal or hepatic impairment
  • * Severe speech impairment or anarthria
  • * Inability to swallow study medication
  • * Women who are pregnant or breast feeding
  • * History of alcohol or substance abuse within the last 12 months
  • * Current use of VMAT2 inhibitor (tetrabenazine, deutetrabenazine, valbenazine)
  • * Concurrent participation in any other investigational drug trials
  • * EKG QTcF\> 500 mse

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vanderbilt University Medical Center,

Amy E Brown, MD, PRINCIPAL_INVESTIGATOR, Vanderbilt University Medical Center

Study Record Dates

2026-04-01